China Expects Earlier Start Of National Marketing Authorization Holder System
Executive Summary
After one year of testing the waters, China’s Drug Marketing Authorization Holder system is likely to have an earlier than expected start to the launch of final law amendment procedures, since the pilot scheme has significantly reduced investment duplication and encouraged pharma companies to file more innovative drug applications.